pharmaceuticals

generic drugs

Big Downside Ahead for Raptor?

Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) was downgraded by Oppenheimer to an Underperform rating from Perform with an $8 price target, implying a downside of about 45% from current prices. Ultimately ...
Read Full Story »
Marijuana Plants

IPO of Zynerba Pharmaceuticals Targets Cannabinoid Therapeutics

Zynerba Pharmaceuticals Inc. has filed an S-1 form with the U.S. Securities and Exchange Commission for its initial public offering (IPO). No terms were given in the filing, but the ...
Read Full Story »
biotech

What Celgene Now Means for Juno

As the health care sector remains hot, it is logical to expect ongoing mergers and acquisitions action to continue. Then there are the collaborative efforts within the sector that should continue. ...
Read Full Story »
Pills

Is Big Pharma Advertising Getting Out of Control?

How much are big pharmaceutical companies really spending to get their drugs out there in the public eye? In 2014, these companies spent about $4.5 billion in advertising alone, notably ...
Read Full Story »
Prescription drugs

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must have expected to get some pushback. The group’s initial version ...
Read Full Story »
Pills

Short Sellers Become More Focused on Big Pharma

The short interest data has been released for the June 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
IPO

Ritter Debuts Quietly in IPO Launch

Ritter Pharmaceuticals Inc. (NASDAQ: RTTR) is the latest company to join in on the wave of initial public offerings. In fact, there were 14 or 15 deals on deck to ...
Read Full Story »
generic drugs

Oral Testosterone Pill Could Make Lipocine Worth Substantially More

Lipocine Inc. (NASDAQ: LPCN) may have a huge hit on its hands with the first swallowable oral testosterone treatment. This could revolutionize the testosterone market because users generally have to ...
Read Full Story »
Eli Lilly Logo

Key Analyst Sees Solid Upside in Eli Lilly

Eli Lilly & Co. (NYSE: LLY) has made a big splash in the market over the past year. A key analyst sees this trend continuing despite some potential near-term headwinds. ...
Read Full Story »
Merger

What Allergan Is Looking to Add With Kythera

The health care sector has been red hot over the past year, feeding numerous possibilities for mergers and acquisitions. Allergan PLC (NYSE: AGN) decided to strike while the iron was ...
Read Full Story »
generic drugs

How Synergy Is Bringing the Ultimate Relief to Shareholders

Usually, pharmaceutical companies are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
health care

Is Sunesis Coming Back From the Dead?

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) was making moves as the week drew to a close. This company was part of the red-hot health care sector, but it really did not ...
Read Full Story »
Prescription drugs

Short Sellers Back Off Big Pharma

The short interest data has been released for the May 29 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
buy sell

Why MannKind Could Be an Endless Tug-of-War Stock

MannKind Corp. (NASDAQ: MNKD) is still one of the biggest battleground stocks out there in the realm of biotech and emerging pharma. After getting U.S. Food and Drug Administration (FDA) ...
Read Full Story »
generic drugs

Is the Teva and Mylan Merger Fight Going to Turn Away Shareholders?

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V. (NASDAQ: ...
Read Full Story »